An Open- label, randomized, two-sequence, crossover Study of Upadacitinib in Healthy Male and Female Healthy Adults

Trial Profile

An Open- label, randomized, two-sequence, crossover Study of Upadacitinib in Healthy Male and Female Healthy Adults

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Nov 2017

At a glance

  • Drugs Upadacitinib (Primary) ; Ketoconazole
  • Indications Autoimmune disorders
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 01 Nov 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top